Scilex Holding Company Common Stock
SCLXStock
$8.79+37.00%52W
Market Cap$78.29M
P/E—
Div yield—
Beta1.72
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-40.40%
Price vs S&P 500 (4W)56.21%
VGM Score58.91
Market Capitalization$78.29M
Earnings Surprise History
Q4 25-2.21est. -0.48
Q1 26-4.76est. —
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
2.17
2.17
2.17
2.17
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SCLXScilex Holding Company Common Stock | C | C | B | $8.79 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Scilex Holding Co develops non-opioid pain management therapeutics for acute and chronic pain conditions. Commercial products include ZTlido (lidocaine topical system for postherpetic neuralgia) and Gloperba (colchicine oral solution for gout flare prevention). The clinical pipeline comprises SP-102 (corticosteroid gel for epidural injection), SP-103 (enhanced lidocaine formulation), and SP-104 (low-dose naltrexone capsule).